Pod Insights a16z Podcast a16z Podcast | Shifting Risk Mindsets, From Tech to Bio About this episode What challenges do first-time founders or tech founders encounter when building companies in the bio space, and how do they differ from traditional tech companies? In this hallway-style conversation episode of the a16z Podcast (originally recorded as a video), a16z bio team general partners Vijay Pande and Jorge Conde, with Jeff Low discuss the mindset shifts involved in building bio (particularly therapeutics) companies. They cover everything from different paths to market and different partnerships (including pharma) to different timelines and milestones for validating the product and business itself. But how do we get to a common language that bridges the worlds of tech and bio?
Transcript 0:00 Speaker 3 Welcome to the A16Z podcast. Today we're having another of our Holly style conversations based on videos that are also available on our YouTube channel at YouTube.com slash C slash A16Z videos. How can bio and therapeutics founders learn to speak the languages of tech and bio? In this hallway cell conversation, A16Z bioteam partners, including general partners, Jorge Conte and Bij Pondi with Jeff Lowe, discuss the mindset shifts involved in building biocompanies, therapeutics companies in particular. They cover paths to market timelines and more.
0:33 Speaker 0 So welcome. Here today we have the A16Z bio team, uh Vijay Pandey, Jorge Conde and Jeffrey Lowe joining. And what we want to talk about today is uh some of the challenges for entrepreneurs investing um and building companies in the biospace broadly. And especially in ways that um that might deliver uh uh differ a bit from the tech in the tech companies, traditional tech companies. And certainly I want to make sure we focus on many of the common pitfalls that we see uh uh entrepreneurs um uh stumble into in this space. So with that, um, Jeffrey, um, you spent a lot of time thinking about that. In your mind, um, what do you think is the top issue that uh an entrepreneur in this space faces when they start to think about um innovating and building a company in the biospace?
1:21 Speaker 2 I think it's about speaking a new language. So you have you know, tech entrepreneurs and technical founders coming in and speaking a language that is very geared toward a tech audience, having a new technology. And I think what we're so interested in is bringing these new technologies to the biospace. And how do you translate that to your partners? How do you translate that to your potential funders? How do you translate that to the media? Because there's something new here and something new and different is something that they often have difficulty translating to people doing something used to doing something in the same way as previously.
1:54 Speaker 1 Yeah, or even I mean, some of these founders, while they're in computer science or engineering, they've actually never founded a company before. So they're not even familiar with how the tech side works. Either way, there's tons of pitfalls going into the biospace.
2:06 Speaker 2 And what do you think is is different about these this class of companies that you know makes it interesting in the first place?
2:12 Speaker 1 Yeah, I mean, first off is that often these companies have to prove that their technology works and is useful and the um the elements necessary for proof are relatively high bar, uh high barrier to pass. And so, you know, you could get early proof of concept deals and that will look good. You might have like five deals and it'll be like a couple hundred K each. But in reality, those are so easy to get that that's it's maybe it sounds more impressive than it is getting really big upfronts and obviously big biobuckle like deals, that's a whole different game.
2:41 Speaker 2 And what do you think is different this time? Computational techniques and in drug discovery have been around for quite a long time. You know, what's exciting about what's going on now and what's different this time?
2:50 Speaker 1 Yeah, you know, you think about it is that uh people point to AI and machine learning, but really that's I think just a surrogate for the fact that data is being used very efficiently, and then we have so much more data. And we do have techniques that we didn't exist before, but in many ways it's uh it's the data that makes things different. And that we see pharma companies and biotechs and startups taking themselves not as biotechs, but as eventually, I think as data science companies. And that becomes that's a very huge uh sort of mindset shift.
3:20 Speaker 0 Yeah, and I think on that, on that point, it's a really interesting moment in time because I think one of the big challenges that startups have had in this space traditionally is that if the time to um uh get to a validation point or a or a value inflection point more specifically is very long and risky and time consuming, um, you do have this temptation to start with the pilot. And I think the uh uh trying to get a bunch of pilot deals um has multiple pitfalls associated with it. First of all, they tend to be relatively small upfronts. And so you have to generate a lot of them to actually generate enough uh additional cash runway to drive you forward. But second of all, most pilot pro uh projects come with expectations associated with them. And so, you know, I don't think it's unique to the biospace, but this concept of death by a thousand pilots is a real one.
4:08 Speaker 0 And so if you're trying to find a company in this space, um, uh, and you're trying to build the company in this space, I should say, you have to be very careful about who you decide to work with on the pilot stance on on the pilot side, because not only do you run the risk of uh working on a lot of small projects, small projects with large companies tend to have scope creep and timeline creep. And so if you were you thought you would finish pilot, you know, uh pilot project and get paid X in Y amount of time. Oftentimes you're getting paid X in something like two X uh two times the Y amount of time. And you're also working a lot harder if there's been scope creep. So it gets really, really challenging to deliver um on multiple pilot projects um in a in in one given time frame.
4:51 Speaker 1 So what's the the solution to that pitfall? I mean, do you just not do the pilot projects and wait for the bigger deals? Do you try to execute them differently?
4:58 Speaker 2 Well, one thing I noticed is I think this is where a lot of these companies start is they start with pilots and they start as a service company. Um they start by saying, hey, I'm gonna go to big pharma. I have a new technology technological break breakthrough. I'm gonna sell that as a pilot to as a service to big pharma companies. And then they can't generate the economics that it would make for a sustainable business. And then they're they're really in a sort of tough spot. And what ultimately the, you know, they go through this idea maze and you know, the what they decide to do often is hey, I need to develop assets in-house. That is because in the biospace, value is created in these huge technical milestones in the very beginning where a lot of these services are used. These are preclinical assets in which there's really not too much value until you bring a drug candidate into the clinic.
5:44 Speaker 2 So these companies go and say, if I want to capture the value for my technology, I need to advance this asset a little bit further down. And then they get into the space where they say, well, I I now am developing drugs.
5:56 Speaker 0 Yeah. And I I think um, so I think that's exactly right. To go back to uh to Vijay's comment or question, rather, and how do you how do you address this issue of the death by a thousand pilots? The first one is you have to be very selective with uh who you work with. In other words, um, it has to be with, and this could be a different company in any given in different uh context, but it has to be a company that fundamentally believes in what you're doing. And that if you can get to a proof point for them, you are immensely valuable for them. Uh the big risk is that everyone does the, you know, I'll just do a you know the free sampling, yeah,
6:33 Speaker 1 like at the
6:33 Speaker 0 mall, right? I'll try a little bit of everything. Yeah,
6:35 Speaker 1 that's always fun.
6:36 Speaker 0 And that's yeah, it's fun if you're sampling. It's hard if you have to make all the samples. Um I think that's the the big challenge. You have to be very careful with who you, you know, you align with on, I think Jeffrey's point, which I think is is exactly right, is you also have to be very thoughtful about where you are in the value chain. And so, you know, there have been there were a lot of biocompanies, for example, that came around around really, really neat science, but that the end for the science was to, for example, um identify a novel target. And in this case, we're talking about a novel target. We're talking about the piece of biology that you want a drug to um to inner to intersect with to impact the progression of the disease. And so the problem with that is pharma companies are swimming in targets, right? Like the problem they're trying to solve for is how do I fill in my pipeline?
7:23 Speaker 1 Yeah, often they think targets should be free anyways. Exactly.
7:25 Speaker 0 And then there are a lot of pre-competitive efforts to make targets free and basically win on on the therapy on the drug development process piece. And so if your platform is to identify novel targets, it's gonna actually be very hard. That's sort of the end of the of the of the line for your what your technology can do. It's really hard to capture value there.
7:41 Speaker 2 Yeah.
7:42 Speaker 0 Um, and certainly hard to get that from a collaboration standpoint. If on the other hand, you somehow had a magical um tool that could predict which drug was likely to fail in a phase three trial, you can imagine that that you'd be able to capture a lot of value there. So it really is where you are in the value chain.
7:56 Speaker 1 Well, and another pitfall I see is that you and I see those main different types of technologies. It could be, you know, machine learning or compute, or it could be like a new type of structural biology technique, whatever the technology is, they got the cool technology. They think this will change drug design. And so then they go to pharma and they try to sell it. And pharma's not convinced yet. Uh, it's like my kids uh with new foods and they don't want to try it until they really know that they really like it. And then they love it and it goes, but the beginning's really hard. And so then you decide, okay, we can't try it. Uh, we we can't sell it to pharma for what we think it's worth. So we're gonna design drugs, but we don't know anything about designing drugs. And and and then that can also be a very dangerous road. So I I don't know how you deal with that pitfall. Do you just sort of try to stay away from that from the beginning and sort of honestly never crossed that line, or do you plan to do that from the beginning?
8:43 Speaker 0 Yeah, well, I I, you know, and uh Jeff Free alluded to this a few minutes back. I think if you look at the history of of sort of the biotech startup ecosystem, you know, a relatively common journey is that is say I have this interesting technology um or platform. I'm gonna do a couple of early stage business development deals. And then my grand vision and hope is that eventually so I can develop drugs for them for my partners and capture some piece of the economics of the downstream value. But my ultimate vision and goal for my company is that I'll eventually get into developing my own drugs and where I'll keep, you know, all of the economics or the majority of the the of the economics. And it's a that's a really hard sort of uh transition to make. And frankly, not many could companies. And the teams aren't set up for it. That's right. Um, and they they aren't set up for it.
9:29 Speaker 0 So I would say there's two things here. One is going back to the pilot concept that who you partner with matters, what they want, how they value um, and how they see what value you bring to the table matters, which I think leads to a second uh point, which is business development in the biospace is a fundamentally strategic um uh advantage to have. If you have a team that is good at structuring business development deals, in other words, that has experience in the space, that allows you to actually help bridge what is often a very fatal chasm for. A lot of companies, how to figure out how to set up early stage deals with pharma companies where you're getting value from the larger partner because the larger partner can obviously can deliver a lot of value. How you're figuring out ways that you can capture some of the downstream value if your approach works, right?
10:15 Speaker 0 So this, you know, downstream milestones and royalties and all of those things. And importantly, how to make sure that you structure these things in a way that you haven't fully encumbered your platform so that you can in fact do things on your own in the future if you choose to, or do things with do things with other partners in the future if it makes sense. Right.
10:34 Speaker 1 I mean, we'll yet another pitfalls that the platform sometimes is a thing that's we find very exciting. But then the company sort of has uh finally actually get through all the things we talked about. And now they got to deal with the fact that that they were successful and with this one asset, and now maybe they're tempted to dish to the platform. And I could see the value and uh sort of just pushing on hard with what works, but you know, how do we sort of balance that? Yeah, especially nowadays where the platform really could be really valuable if these technologies are as powerful as we think they could be.
11:03 Speaker 0 Well, I've certainly seen that in in, you know, in close uh the first hand experience where you have a platform that could be very valuable and precisely because it's a productive platform, you find a an asset, in this case, a specific potential drug, and very quickly all focus goes towards um, you know, how we make sure you maximize the value, uh, minimize the risk and successfully commercializing said drug. And it's a really interesting thing, and it happens almost overnight that as soon as you have that, all of the conversations start to focus on well, we could always use more resources on making sure that the drug program succeeds and there's only a fixed pool of resources generally speaking. And so what ends up happening is the platform gets started. And I think that happens time and time again. I think one way to address that um is of course through business development partnerships.
11:51 Speaker 0 Um, and uh even then you don't entirely alleviate the pressure on funding the program ahead of the platform unless you've specifically structured your business development agreement to fully fund the program, right? I mean, that's the that's and that's hard to do, especially if you're an early stage company. But a second way to do that is through innovative structures. And so we've seen this in a couple of examples where companies establish an LC structure, and they basically are able to say for investors that are really uh the believe in the the future of this platform and the productivity of the platform to not just develop uh and one drug asset but multiple drug assets over time, that becomes sort of the parent company of the mothership. And then you have separate LLCs under that that you basically say for drug asset A, I'll bring in new investors and new investors are essentially betting primarily on the success of that drug asset.
12:41 Speaker 0 And so the the parent company has taken a much smaller piece of the economics, but they can now replicate it many, many times because they have the resources to invest in the platform so ensure that future products.
12:53 Speaker 2 Let's be clear why we do this. Umvalidated platform really doesn't have a lot of value. And that's why there's on the first asset, you know, the whole company's value may be riding on this asset because not only is that asset in itself valuable, but it also validates the the efficacy and usefulness of the platform itself. Then you're kind of in this in this uh state where you might have to say, well, I am now a single asset bet because if my first asset from my platform fails, well, maybe I throw out a good platform with a bad asset, or maybe I just have a bad platform, you know, and a bad asset. Some of these other um legal structures are kind of ways to get around that. But you know, it doesn't get around this problem of, hey, the first asset validates the platform and its success or failure, you know, means a lot for this business going forward.
13:40 Speaker 0 Yeah, and we and we we've spoken a little bit about this before. And I think it's an important point to bring up is that there are platforms that um generate uh a drug asset. Um, and therefore you don't know that they're unvalidated by definition because you have one drug asset. And so until that drug asset is approved, you don't really know if the platform is valuable or not. And so therefore all the value does accrue and all the risk does accrue to that that lead asset. But then there are platforms that could be so fundamental in understanding biology and so generalizable that um, you know that you actually want to structure a deal in such a way that someone that only believes in assets will fund that and and you still leave room for uh folks that believe in the platform to support that. Now it's hard to know a priori which is which.
14:26 Speaker 0 And I think that's one of the big challenges here. Our belief, um, or at least I think I speak collectively for the team, is that you know, for platforms that have a engineering like bent to them, they're more likely to fall in the second camp than the first. Um, but that's obviously um the uh the hope and the bet that we're making in the entrepreneurs and the companies that we're supporting. Um, but yeah, I think that's it's gonna it remains to be seen how over time you make sure that um you're very clear on what kind of platform you're dealing with when you're making in.
14:57 Speaker 2 We've been talking some generalities here. You know, Vijay, you're involved pretty early on in Schrdinger, um, which you know had a very successful collaboration with Nimbus, you know, maybe you could talk about um that example as one where the legal structure was, you know, really successful, made uh help make that company successful.
15:11 Speaker 1 Yeah, I mean, Nimbus was uh, I think one of the early companies that thought about this LLC structure. And so it's kind of interesting that pitfalls can even be just in how you structure the company. Uh, you would think a C core would be a pretty standard thing to do these days. Uh and so I I mean I think it's still early, and I think it's a new thing. Uh and I uh therefore uh the venture community and and startup entrepreneurs will need to get socialized to this, and that will happen in time. You know, I think we've been spending a lot of time talking about therapeutics. I think uh, you know, there's also analogous pitfalls in other areas, like in and diagnostics and you know, especially in the biofront, we're interested in biology quite broadly and and other sort of applications. When I think about that, I mean, there's some applications that might look more like tech companies, depending on how how they're built, but some things like diagnostics will still have to get through regulatory agencies, either Clio or FDA, and there's a whole bunch of pitfalls just there.
15:58 Speaker 1 And I think a lot of times what we're seeing is that it's very important to address those pitfalls by understanding them early and handling them. So I mean, we could talk a little bit about the pitfalls that we see in that diagnostic space.
16:09 Speaker 0 So what why don't we start there? What do you think is the biggest risk um in in diagnostic specific? Yeah,
16:15 Speaker 1 ironically, I think you know, most people think about um the FDA or or CLIA being your your big uh concern. I think reimbursement is probably the first place to start because I wouldn't want to sort of be designing a test without having the confidence that it'll get reimbursed. Otherwise, why bother doing the whole thing? And so, you know, when um I I've been involved in drug design, we usually start with thinking about how we're gonna run the clinical trial and then work backwards uh on the drug design side. I would want to do the same thing on the diagnostic, but start even further upstream, downstream talking about how are we going to get reimbursed, what's the value that we're going to add? And if that's there, then the rest actually we can make our arguments for. And and uh when there's time early on, especially when tech is so powerful that you could go lots of different avenues and it's early, it's sort of directing where you want to take the ship, uh, thinking about that will get you to the right place long term rather than getting to the wrong place and then having to figure out how to pivot from there.
17:04 Speaker 1 Maybe
17:04 Speaker 2 it'd be helpful if you backed up and said, well, how is uh what would a company that's a diagnostics company that's tech driven or built like a tech company look like and how would that be different from uh biology-driven uh diagnostics company. Yeah,
17:16 Speaker 1 I mean, that's a great point. I think one of the things that's we see that's really different is that when you can engineer biology, you don't have this very bespoke process of sort of having scientific discovery, but you have the ability to engineer a process and then repeat this in different indications. So if you're having a cancer test, it could be for whichever cancer, you know, uh uh indication you want based on the data that you have. So why not pick an indication where you feel like the go-to-market is strongest? And for that, it's now talking thinking about the go-to market at the very earliest,
17:43 Speaker 0 earliest of stages. So to just to um take your words out of context a little bit, earliest of stages and diagnostics, and you're talking about go to market with reimbursement. Um one of the challenges, and I think this is more a thought experiment than sort of hard data. But one of the challenges um that at least I've heard about the early stage screening type diagnostics and reimbursement is that a lot of patients don't stay on a plan for a long period of time. And so getting broad-based reimbursement for early screening may not make sense from an ROI perspective for the payer. Um, how do we get around that question?
18:20 Speaker 1 Yeah, this is a one of the fundamental questions in healthcare because um, how do you pay for things for the ROI is is backloaded like five or 10 years. And sort of your insurance company, maybe that doesn't make sense for your economics. There's a couple of different ways. One is that I mean, outside the US, obviously things are different. So that's like the cheating answer uh that you don't get they only get partial credit for. I think uh the uh maybe a somewhat deeper answer is to think about uh um that self-insured payer, sorry, self-insural employers um might be a little more motivated because while people may change plans, they don't change jobs slightly less frequently. But I think, you know, I think uh we've talked about this. We've seen other sort of more interesting financial mechanisms that are coming on board where insurance companies can find ways uh to make these incentives. And I think we'll have to change how paying is done.
19:07 Speaker 1 But at least there's been proposals for that.
19:10 Speaker 0 Yeah, and I think that's that that was one of the interesting ones that I've sort of heard thrown around is the idea, you know, we talk a lot about doing pilot projects with, you know, pharma companies if you're trying to develop a therapeutic. There is this sort of tantalizing um uh potential to do pilot projects with insurers or payers if you're trying to develop something that they need to prove the ROI ROI out for themselves. And that gets really interesting because then you can start with the end in mind as you sort of laid out. Yeah.
19:37 Speaker 1 Great. Well, you know, so we covered therapeutics and diagnostics. Maybe one last thing we could talk about, and then we're maybe running close to time is sort of biology more broadly. Like, so maybe you're not doing something that's going to uh sort of connect with human health, so you'd have to get it done. But like you're let's say a company designing bacteria to do something new. And the bacteria is not gonna be ingested by a human or anything like that. Um now they're sort of different challenges. I mean, there's uh things that may be tempting to look like a temp company because you may have tech behind it, but uh and the deals could be really large. I think this maybe just comes us takes us back full circle to what we talked about on the therapeutic side that the POC still become a problem.
20:15 Speaker 0 Yeah. And I think it's I think those are those are big, I mean that is a big challenge on the therapeutic side. And it's a big challenge on sort of the broader platform, you know, biology side. And to to us, or at least, you know, as we've talked about it as a group collectively, I think what's really interesting is what do you do with that challenge, right? So one way to do it is to say, as to now to go all the way back to the beginning of this conversation is to say, well, maybe you do start off as a service model. Or, you know, in the case of, you know, I don't know what a box, a magic box that could make engineer bacteria would look like, but let's assume that this is something you could productize as an instrument, kind of like what Illumina has done where you sort of now go into this box and and sort of consumables model. And what you do there is you basically start and you sell to the high end of the market first.
21:03 Speaker 0 Right. So what um you know what we saw with happening with sequencing was that obviously in the very early days when you know the the the throughput of the sequencer was low where the cost was very high, the only natural buyer for that was you know large research institutions. And those sort of became the initial sites. And as the as the you know sort of uh performance got better, the market opened up and opened up and opened up and of course, you know, today if you can get a benchtop sequencer for relatively low amount of money and basically any lab can afford that. And so um I think the same is true when you have these other technology platforms. So the big question becomes how do you get to to fundamental POC? In the case of sequencing it was straightforward you could sequence known DNA and basically show that you can generate that same result. In the case of sort of let's take your you know engineered bacteria um is you would want to design a simple set of experiments and I'll go back to your Apollo mission sort of analogy, right?
21:57 Speaker 0 Where you a uh a set of experiments that say I can design basic functionality, it's going to have very high predictability and then over time the level of of complexity that you can design into a system goes up or the throughput goes up or the quality goes up or the cost comes down. And so there are sort of these various variables that folks feel I think feel comfortable around that you can start to sort of march towards you know increased um proof points and eventually get into what you know POC. And the the other thing I'd mention is POC is not the same for all parties. That's right. Right. So you'll have early adopter POC is obviously a near term target than your late adopter POC. And so you should always design for the early adopter POC with a clear path to how you can actually eventually engineer in all the way to the end of the market. Now the one thing I would say I think this is true for all entrepreneurs in this space and this has been my humble experience is, you know, if you're developing technology in the biology space, you should know what your near term killer experiment is and the experiment that if it does not work, it's it's you know kill mode for whatever you're developing.
23:00 Speaker 0 And you should know what that is you should have in your mind what could I show in the next you know six to 12 months that would you know essentially cause me to kill this idea. So A, you should know what it is and B, you should be doing that experiment. The number of times I've talked to entrepreneurs
23:16 Speaker 1 and that's scary because it's a very existential thing, but that's exactly why you've got to do it.
23:20 Speaker 0 Exactly. And the number of times that I've talked to entrepreneurs that have said well yes that we think that's a big experiment but we have all this other stuff going on. So we're gonna get to it. And that's I think for everyone's sake it's important to do the kill, you know, the kill test early. Yeah. Yeah. Um so that's that's always been my view on there's POC and then well there's the equivalent of proof to me you know it's proof of concept and then you know the proof to me that this hasn't failed yes you know in a fundamental mode. And so you should know what that looks like and do it early.
23:47 Speaker 1 So maybe one last pitfall we could talk about is just pitfall for getting yourself funded. So if you think about like three poles, we got consumer enterprise and biotech. And the space that we're talking about sometimes looks more or it's like some combination of those. You might have uh a a company that's using technology in healthcare but direct to consumer, something that's more enterprise focused, something that is maybe more therapeutic or diagnostic focused. And each one of those has fairly different ways of proving to investors that you're making progress. You know consumer maybe it's about the graph, you know, uh DAU versus MAU and so on for enterprise it might be revenue for biotech might be hitting milestones. And so a lot of the challenges here I think is uh you know trying to figure out where you know the pitfalls of figuring out uh we're how can you prove that it's really working when it's uh some complicated mix of all these things.
24:36 Speaker 2 And then which is the best investor actually at each stage of the business. So I mean there could be periods of time where it's you know much more tech like building a platform and then there are periods of time where there might be a lot of science risk and you know tech investors, I mean ultimately they're just not set up to take on science risk in the way that biotech investors you know have arranged themselves. So you know how do these companies go and pick which thing it is that they should be doing it and who they should get money from
25:02 Speaker 0 yeah I would say a couple of things. One is uh you know in some cases it might make sense to actually have a hybrid, right? Because these companies are hybrid I could think of one firm like yeah exactly think of one firm who spends their time thinking at both at both levels right from the bio side and from the sort of the the the the more tech side um and it also makes sense to think about how you would build up your investor syndicate, right? And so I think one thing that's a truism for all entrepreneurs is when you're raising this round you should always be thinking about what the next round is going to look like. And that's not just in terms of what you know valuation metrics you hope to hit, what milestones you hope to clear to make sure you hit the inflection points to allow you to hit the valuation metrics, but also who's involved today and who might be involved tomorrow.
25:48 Speaker 0 And you know one thing that we've seen work before is you know um you see a traditional bio investor connect with traditional tech investor so they can each side can help the other um know what they don't know and sort of get comfortable and then as the sort of company gets more mature that mix of the syndicate might change either becomes more traditional bio or more traditional tech um and then eventually you get to of course late stage type investors. So that's one way to approach it. The other one is to go back to what where you started VJ which is to be very clear on what metrics do you think you can prove over the course of whatever the funding amount uh the funding period is the runway and then base your investors on what you're going to prove because again different audiences care about different POCs, whether it's the graph or the milestone or what have you. And I think being very clear to yourself about that up front should help you define how you uh seek an investor base.
26:38 Speaker 0 And then the final point I would make is I think the initial um comment that VJ uh excuse me that Jeffrey made which is um sometimes we speak two two different languages. And so you know you you need to be if you if you're not fluent in two languages, you should definitely be fluent in one and you know functional in the other. And I think it's important to understand what the two languages are so that you can ensure that if you intend to bring bioinvestors online in the future that you set up a company and set up a a sort of a common set of languages and ideas that they can understand.
Previous Company Building in Crypto: A Conversation between Brian Armstrong and Chris Dixon Next What's Next for Education Startups Page updated August 25, 2026 · transcript and summary are machine-generated